Meda, which MYL attempted to acquire in 2014, sells specialty drugs, branded generics, and OTC products in 150 countries. Meda is a reasonable (but smaller) alternative to PRGO, which MYL attempted to acquire in 2015.
The nominal deal value is $9.9B, including the assumption of $2.7B in debt.
MYL fell 9% in AH trading, although some of the drop may be attributable to MYL’s tepid guidance for 2016 non-GAAP EPS of $4.85-$5.10 (#msg-120453066).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.